Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT400 plus CHOP in untreated CD20-positive DLBCL
NCT02772822Phase 3Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Jun 2016
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ripertamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Sinocelltech Group Limited. Status: unknown.
02
Drugs
ripertamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02772822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02772822.